Review article: fungal alterations in inflammatory bowel diseases
- PMID: 31648369
- DOI: 10.1111/apt.15523
Review article: fungal alterations in inflammatory bowel diseases
Abstract
Background: Emerging data suggest that alterations in gut fungi may be associated with the pathogenesis of inflammatory bowel disease (IBD). In healthy individuals, gut commensal fungi act synergistically with other members of the microbiota to maintain homeostasis but their role in IBD is less clear.
Aim: To review the role of gut fungi and their trans-kingdom interactions with bacteria in IBD METHODS: A literature search was conducted on Ovid and Pubmed to select relevant animal and human studies that have reported fungi and IBD.
Results: There is an increased total fungal load particularly of Candida and Malassezia species in the faeces and mucosa of Crohn's disease patients, and a lower fungal diversity in the faeces of ulcerative colitis patients. Caspase recruitment domain-containing protein (CARD)-9 polymorphism in Crohn's disease patients favours Malassezia colonisation that worsens gut inflammation. Diet high in carbohydrates increased the total abundance of Candida species, whereas protein-rich diet had the opposite effect. Anti-fungal therapies are mostly used to treat Candida albicans or Histoplasma capsulatum infections in IBD, whereas pilot studies of supplementing fungal probiotics Saccharomycopsis fibuligera, Saccharomyces boulardii and Saccharomyces cerevisiae CNCM I-3856 strain showed therapeutic effects in IBD.
Conclusions: Gut fungi are altered in patients with Crohn's disease and ulcerative colitis. Modulation of the fungal microbiota can be considered as a therapeutic approach for IBD. Future research should focus on understanding how the fungal microbiota interacts with other components of the gut microbiota in association with the pathogenesis and development of IBD.
© 2019 John Wiley & Sons Ltd.
Similar articles
-
Review of Saccharomyces boulardii as a treatment option in IBD.Immunopharmacol Immunotoxicol. 2018 Dec;40(6):465-475. doi: 10.1080/08923973.2018.1469143. Epub 2018 May 17. Immunopharmacol Immunotoxicol. 2018. PMID: 29771163 Review.
-
Fungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease.Inflamm Bowel Dis. 2015 Aug;21(8):1948-56. doi: 10.1097/MIB.0000000000000454. Inflamm Bowel Dis. 2015. PMID: 26083617 Free PMC article.
-
Fungal microbiota dysbiosis in IBD.Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3. Gut. 2017. PMID: 26843508 Free PMC article.
-
Microbiota in Inflammatory Bowel Disease Pathogenesis and Therapy: Is It All About Diet?Nutr Clin Pract. 2015 Dec;30(6):760-79. doi: 10.1177/0884533615606898. Epub 2015 Oct 9. Nutr Clin Pract. 2015. PMID: 26452390 Review.
-
Gut mycobiome: The probable determinative role of fungi in IBD patients.Mycoses. 2021 May;64(5):468-476. doi: 10.1111/myc.13238. Epub 2021 Feb 3. Mycoses. 2021. PMID: 33421192 Review.
Cited by
-
Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study.PLoS One. 2022 Dec 30;17(12):e0277576. doi: 10.1371/journal.pone.0277576. eCollection 2022. PLoS One. 2022. PMID: 36584073 Free PMC article.
-
A comprehensive guide to assess gut mycobiome and its role in pathogenesis and treatment of inflammatory bowel disease.Indian J Gastroenterol. 2024 Feb;43(1):112-128. doi: 10.1007/s12664-023-01510-0. Epub 2024 Feb 27. Indian J Gastroenterol. 2024. PMID: 38409485 Review.
-
Drug Targeting of Inflammatory Bowel Diseases by Biomolecules.Nanomaterials (Basel). 2021 Aug 10;11(8):2035. doi: 10.3390/nano11082035. Nanomaterials (Basel). 2021. PMID: 34443866 Free PMC article. Review.
-
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy.Protein Cell. 2021 May;12(5):331-345. doi: 10.1007/s13238-020-00745-3. Epub 2020 Jun 29. Protein Cell. 2021. PMID: 32601832 Free PMC article. Review.
-
Mesenchymal (Stem) Stromal Cells Based as New Therapeutic Alternative in Inflammatory Bowel Disease: Basic Mechanisms, Experimental and Clinical Evidence, and Challenges.Int J Mol Sci. 2022 Aug 10;23(16):8905. doi: 10.3390/ijms23168905. Int J Mol Sci. 2022. PMID: 36012170 Free PMC article. Review.
References
REFERENCES
-
- Bernstein CN, Shanahan F. Disorders of a modern lifestyle-reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57:1185-1191.
-
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-2778.
-
- Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489-1499.
-
- Glocker E-O, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033-2045.
-
- Chu H, Khosravi A, Kusumawardhani IP, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352:1116-1120.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical